Is this you? Create Your Porfile
Avatar

Joshua Michael Lang

University of Wisconsin-Madison

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Joshua Michael Lang is active.

Explore More

Publication

Featured researches published by Joshua Michael Lang.

Journal of Clinical Oncology | 2017

A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.

Daniel P. Petrylak; Raymond P. Perez; Jingsong Zhang; David C. Smith; Joseph D. Ruether; Srikala S. Sridhar; Randeep Sangha; Joshua Michael Lang; Elisabeth I. Heath; Jaime R. Merchan; Elaina M. Gartner; Rong Chu; Banmeet Anand; Fernando Donate; Lynnae Jackson; Jeffrey Adams; Amal Melhem-Bertrandt; Jonathan E. Rosenberg

Journal of Clinical Oncology | 2017

Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.

Waddah Arafat; Charlotte Stahlfeld; Jamie M. Sperger; Erika Heninger; Dharmesh Gopalakrishnan; Pedro C. Barata; Marcelo Lamenza; Sarah Devonshire; Nita Hoxha; Pam Profusek; Brian I. Rini; Moshe Chaim Ornstein; Jorge A. Garcia; Christos Kyriakopoulos; Joshua Michael Lang; Petros Grivas

Journal of Clinical Oncology | 2018

Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).

Jonathan E. Rosenberg; Srikala S. Sridhar; Jingsong Zhang; David C. Smith; Joseph D. Ruether; Thomas W. Flaig; Joaquina Baranda; Joshua Michael Lang; Elizabeth R. Plimack; Randeep Sangha; Elisabeth I. Heath; Jaime R. Merchan; David I. Quinn; Sandy Srinivas; Matthew I. Milowsky; Chunzhang Wu; Elaina M. Gartner; Amal Melhem-Bertrandt; Daniel P. Petrylak

Journal of Clinical Oncology | 2018

A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

Ulka N. Vaishampayan; Vivek Narayan; David Wise; Joshua Michael Lang; Benjamin H Lowentritt; Begoña Mellado; Joan Carles; M Isabel Sáez; Wassim Abida; Mary-Ellen Taplin; Arun Azad; Karrie Wang; Olena Barbash; Geraldine Ferron-Brady; Doug Fecteau; Ahmed Hussein Khaled; Arindam Dhar; Johann S. de Bono

Journal of Clinical Oncology | 2017

Therapeutic targeting of tumor-associated macrophages through microscale engineering of the prostate cancer microenvironment.

David Kosoff; Jiaquan Yu; Jennifer L. Schehr; David J. Beebe; Joshua Michael Lang

Journal of Clinical Oncology | 2018

Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.

Arkadiusz Z. Dudek; Li C Liu; Ajjai Alva; Mark N. Stein; Shilpa Gupta; Costantine Albany; Monika Joshi; Yousef Zakharia; Joshua Michael Lang; James K. Schwarz; Anas Al-Janadi

Journal of Clinical Oncology | 2018

Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.

Xiao X. Wei; Rana R. McKay; Kathryn P. Gray; Walter M. Stadler; David F. McDermott; Bradley Alexander McGregor; Neeraj Agarwal; Christos Kyriakopoulos; Benedito A. Carneiro; Tracy L. Rose; Yousef Zakharia; David A. Braun; Kenneth J. Livak; Catherine J. Wu; Eliezer M. Van Allen; Sabina Signoretti; Joshua Michael Lang; F. Stephen Hodi; Toni K. Choueiri; Lauren C. Harshman

Journal of Clinical Oncology | 2018

Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.

Daniel P. Petrylak; David C. Smith; Thomas W. Flaig; Jingsong Zhang; Srikala S. Sridhar; Joseph D. Ruether; Elizabeth R. Plimack; Jaime R. Merchan; David I. Quinn; Deepak Kilari; Sandy Srinivas; Joaquina Baranda; Joshua Michael Lang; Matthew I. Milowsky; Matt D. Galsky; Alexander I. Spira; Elaina M. Gartner; Chunzhang Wu; Amal Melhem-Bertrandt; Jonathan E. Rosenberg

Journal of Clinical Oncology | 2017

Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy.

Kimberly Peihsi Ku; Joshua Michael Lang; Jamie M. Sperger; Scott M. Dehm; Manish Kohli; Liguo Wang; Liewei Wang; Scott T. Tagawa; Howard I. Scher

Journal of Clinical Oncology | 2017

Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.

Waddah Arafat; Joshua A. Desotelle; Tamara S. Rodems; Rana R. McKay; Jason Abel; Toni K. Choueiri; Joshua Michael Lang

Explore More

Collaboration

Dive into the Joshua Michael Lang's collaboration.

Top Co-Authors
Avatar

Daniel P. Petrylak

Yale University

View shared research outputs
Top Co-Authors
Avatar

David C. Smith

University of Michigan

View shared research outputs
Top Co-Authors
Avatar

Elaina M. Gartner

Seattle Genetics

View shared research outputs
Top Co-Authors
Avatar

Jaime R. Merchan

University of Miami

View shared research outputs
Top Co-Authors
Avatar

Jingsong Zhang

University of South Florida

View shared research outputs
Top Co-Authors
Avatar

Jonathan E. Rosenberg

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors
Avatar

Joseph D. Ruether

Tom Baker Cancer Centre

View shared research outputs
Top Co-Authors
Avatar

Srikala S. Sridhar

Princess Margaret Cancer Centre

View shared research outputs
Top Co-Authors
Avatar

Elisabeth I. Heath

Wayne State University

View shared research outputs
Top Co-Authors
Avatar

Jamie M. Sperger

University of Wisconsin-Madison

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge